Skip to main content
Clinical Trials/NCT02159079
NCT02159079
Completed
Not Applicable

A Phase II/III Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction

Vanderbilt University1 site in 1 country30 target enrollmentJuly 2014
ConditionsSepsis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Vanderbilt University
Enrollment
30
Locations
1
Primary Endpoint
ICU-free Days to 14 Days After Enrollment
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Sepsis is a common inflammatory response to infection characterized by hypovolemia and vasodilation for which early administration of intravenous fluids has been suggested to improve outcomes. The ideal fluid balance following initial resuscitation is unclear. Septic patients treated in the intensive care unit commonly receive significant volumes of intravenous fluids with resultant positive fluid balance for up to a week after their initial resuscitation. Observational studies have associated fluid receipt and positive fluid balance in patients with severe sepsis and septic shock with increased mortality but are inherently limited by indication bias. In order to determine the optimal approach to fluid management following resuscitation in patients with severe sepsis and septic shock, a randomized controlled trial is needed. The primary hypothesis of this study is that, compared to usual care, a conservative approach to fluid management after resuscitation in patients with sepsis and cardiopulmonary dysfunction will increase intensive care unit free days.

Registry
clinicaltrials.gov
Start Date
July 2014
End Date
April 2016
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Matthew Semler

Fellow in Pulmonary and Critical Care Medicine

Vanderbilt University

Eligibility Criteria

Inclusion Criteria

  • ICU patients
  • Sepsis as defined by at least two systemic inflammatory response syndrome criteria and receipt of antimicrobial therapy
  • Cardiopulmonary dysfunction as defined shock or respiratory failure

Exclusion Criteria

  • Inability to obtain consent
  • Greater than 48 hours since inclusion criteria initially met
  • Allergy to furosemide AND bumetanide
  • Rhabdomyolysis with creatinine kinase \> 5000 U/L
  • Hypercalcemia with calcium \>11 mg/dL
  • Diabetic Ketoacidosis requiring continuous insulin infusion
  • Tumor Lysis Syndrome diagnosed clinically
  • Pancreatitis diagnosed clinically
  • Chronic Hypoxic Respiratory Failure with Home Oxygen Use of FiO2≥0.3
  • Chronic ventilator dependence

Outcomes

Primary Outcomes

ICU-free Days to 14 Days After Enrollment

Time Frame: 14 days

The primary outcome will be the number of ICU-free days to day 14 (defined as the number days alive and outside of the intensive care unit in the first 14 days after enrollment).

Secondary Outcomes

  • Renal Replacement Therapy-free Days to Day 14(14 days)
  • Highest Plasma Creatinine Between Enrollment and 28 Days After Enrollment(28 days)
  • In-hospital Mortality to Day 14(14 days)
  • Highest Stage of Acute Kidney Injury(28 days)
  • Ventilator-free Days to Day 14(14 days)
  • Receipt of Renal Replacement Therapy(28 days)

Study Sites (1)

Loading locations...

Similar Trials